Neuroprotection in Diabetes Retinal Disease: An Unmet Medical Need
International Journal of Molecular Sciences · 16.01.2026 · 27 (2) · 901
DOI: 10.3390/ijms27020901 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.01.2026. Verfasst von Hugo Ramos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Neuroprotection, Neuroprotective Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Economía y Competitividad.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetic retinopathy (DR) has been classically considered a microvascular disease with all diagnostic and therapeutic resources focusing on its vascular components. However, during the past years, the obtained evidence highlighted the critical pathogenic role of early neuronal impairment redefining DR as a neurovascular complication. Retinal neurodegeneration is triggered by chronic hyperglycemia, which activates harmful biochemical pathways that lead to oxidative stress, metabolic overload, glutamate excitotoxicity, inflammation, and neurotrophic factor deficiency. These drivers of neurodegeneration can precede detectable vascular abnormalities. Simultaneously, endothelial injury, pericyte loss, and breakdown of the blood–retinal barrier compromise neurovascular unit integrity and establish a damaging cyclic loop in which neuronal and vascular dysfunctions reinforce each other. The interindividual variability of these processes highlights the need to properly redefine patient phenotyping by using advanced imaging and functional biomarkers. This would allow early detection of neurodegeneration and patient subtype classification. Nonetheless, translation of therapies based on neuroprotection has been limited by classical focus on vascular impairment. To meet this need, several strategies are emerging, with the most promising being those delivered through innovative ocular routes such as topical formulations, sustained-release implants, or nanocarriers. Future advances will depend on proper guidance of these therapies by integrating personalized medicine with multimodal biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), 28029 Madrid, Spain.
ORCID-Profile: Hugo Ramos, Olga Simó-Servat
Förderung
- Ministerio de Economía y Competitividad
Zitieren
APA
Ramos, H., & Simó-Servat, O. (2026). Neuroprotection in Diabetes Retinal Disease: An Unmet Medical Need. International Journal of Molecular Sciences, 27(2), 901. https://doi.org/10.3390/ijms27020901
Vancouver
Ramos H, Simó-Servat O. Neuroprotection in Diabetes Retinal Disease: An Unmet Medical Need. International Journal of Molecular Sciences. 2026;27(2):901. doi:10.3390/ijms27020901
BibTeX
@article{Ramos2026,
author = {Ramos, Hugo and Simó-Servat, Olga},
title = {Neuroprotection in Diabetes Retinal Disease: An Unmet Medical Need},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {901},
doi = {10.3390/ijms27020901}
}
EUVIMED